BMRN — BioMarin Pharmaceutical Inc.

Summary of BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $766 million for Q1 2026, reflecting year-over-year growth driven by strong demand in Enzyme Therapies and Voxzogo.
• Enzyme Therapies Revenue: Increased by 6% year-over-year, led by Vimizim, Naglazyme, and Brineura, despite lower revenue from Roctavian and Kuvan.
• Voxzogo Revenue: Strong patient demand with new patient starts up over 20% year-over-year.
• Non-GAAP Diluted EPS: Reported at $0.76, impacted by increased operating expenses and a $31 million charge related to Naglazyme manufacturing.
• Updated 2026 Guidance: Total revenue guidance raised to $3.825 billion - $3.925 billion (20% growth), with Enzyme Therapies revenue guidance increased to $2.725 billion - $2.775 billion (30% growth). Non-GAAP diluted EPS guidance updated to $4.85 - $5.05.

2. Strategic Updates and Business Highlights

• Amicus Acquisition: Completed last week, adding Galafold and Pombility and Opfolda to BioMarin's portfolio. The integration plan is underway to enhance growth potential.
• Palynziq Expansion: Strong interest following the adolescent label expansion in the U.S. is expected to drive future growth.
• Voxzogo: Continued focus on younger patients, with a significant portion of new patient starts coming from children under two years old.
• Regulatory Submissions: sNDA for Voxzogo submitted for full approval, with pivotal results for Voxzogo in hypochondroplasia and BMN-401 for ENPP1 deficiency expected in Q2.

3. Forward Guidance and Outlook

• Anticipated revenue growth in 2026 is expected to be heavily weighted towards the second half, with over 55% of total revenues projected to be recognized in that period.
• The company expects Q2 non-GAAP diluted EPS to be modestly higher than Q1, with most profitability anticipated in Q3 and Q4.
• The Amicus acquisition is expected to be slightly dilutive in 2026 but accretive in the first twelve months post-acquisition and substantially accretive beginning in 2027.

4. Bad News, Challenges, or Points of Concern

• Cost of Sales Impact: A significant charge from an unsuccessful Naglazyme manufacturing campaign negatively impacted margins and earnings.
• Order Timing Dynamics: Revenue growth was partially offset by order timing, particularly for Palynziq and Voxzogo, leading to a disconnect between patient demand growth and reported revenues.
• Competitive Pressures: The entry of competitors into the market for Voxzogo raises concerns about patient switching and market share, particularly in the context of new therapies being developed.

5. Notable Q&A Insights

• Integration of Amicus: Management emphasized the potential for growth through improved diagnosis rates for Galafold and switching opportunities for Pombility and Opfolda.
• Voxzogo Adoption: The company is focused on driving diagnosis and treatment urgency for hypochondroplasia, with a significant increase in identified patients and a reduction in age at diagnosis.
• ITC Hearing Update: Management provided an update on the ITC hearing regarding patent infringement, indicating a decision is expected by August 21.
• BMN-333 Development: Discussion on the decision to pursue a superiority trial for BMN-333, with a focus on establishing it as a next-generation standard of care for achondroplasia.

Overall, BioMarin is positioned for growth in 2026, bolstered by the Amicus acquisition and strong demand for its products, despite facing challenges related to competition and operational costs.